Self-administration of mepolizumab via an autoinjector: the patient experience

This abstract will be presented at ERS 2019 in Madrid, Spain.

Dr. Marie Gienger, is presenting this Encore on behalf of all authors with their permissions.

Introduction/Background: Mepolizumab (Nucala^®) is licensed for severe eosinophilic asthma (SEA). A prefilled autoinjector (AI) has been developed to enable in-clinic and at-home, self-administration which may improve the patient treatment experience (PTE).

Objectives: Summarise mepolizumab AI PTE.

Methods: A single-arm, PhIIIa study in SEA evaluated the real-world use of the mepolizumab AI (N = 159). Quantitative questionnaires (QQ) were administered to capture the PTE of self-administration.

Results:

• ≥ 98% patients were able to successfully inject their 3rd dose of mepolizumab using the AI

• 96% were satisfied/very satisfied with self-administration via the AI at home

• 96% preferred self-injection at home, compared to in-clinic by a health care professional (HCP) (only patients who previously received mepolizumab administered by a HCP were asked)

Conclusions: Nearly all patients successfully self-administered mepolizumab via the AI at week 8 and patient satisfaction using the device at home was high.

Funding: GSK [GSK204959, NCT03099096]

Table 1 Successful injections and PTE QQ results summary.

	AI IFU+P* (N = 104)	AI IFU* (N = 55)
Two device IFU packages were tested: ‘standard IFU + pictogram’ (i.e. Quick Reference Guide) (IFU+P), and ‘standard IFU’ (IFU). 1 There were no subjects/caregivers in the ‚Very dissatisfied‘ and ‚Dissatisfied‘ categories. ^ Only subjects who previously received HCP-administered mepolizumab asked
Attempted injections (week 8), n	103	54
Successful injections (week 8)	102 (99%)	53 (98%)
Satisfaction using device at home1, n	102	51
Neither satisfied/dissatisfied	4 (4%)	2 (4%)
Satisfied	15 (15%)	15 (29%)
Very satisfied	83 (81%)	34 (67%)
Setting preference, n	47^	25^
AI at home	45 (96%)	24 (96%)
Injection administered by HCP	2 (4%)	1 (4%)